ITS to provide pre-market trading in Aktis Oncology U.S. IPO

The international trading platform ITS will offer investors the opportunity to purchase shares of Aktis Oncology (AKTS), a U.S. company developing next-generation radiopharmaceuticals for cancer treatment. The IPO is scheduled on Nasdaq for January 9, 2026.

Investors can place orders starting from 15:00 Astana time (10:00 UTC) – 4.5 hours before the main U.S. trading session opens. Trading proceeds with no volume restrictions or lock-up period. Liquidity is ensured by a market maker providing two-way quotes.

ITS regularly provides access to pre-market trading in companies conducting IPOs on U.S. exchanges. Investors can use the pricing disclosed in IPO documents as reference points. 

This material does not constitute investment advice or an offer to purchase securities. ITS reminds investors that investing in securities, especially at the IPO stage, involves elevated risks. Following the initial listing, shares may exhibit high volatility in the first days of trading.

 

About ITS

ITS is an international liquidity hub. Central to ITS's business model are the principles of best execution and smart order routing technology. These principles enable investors to execute securities transactions at the best prices available on the global financial market, regardless of the transaction volume.  

ITS's direct clients include professional securities market participants from Kazakhstan and other countries, such as financial intermediaries who are accredited and directly registered at the AIFC. Investors, both private individuals and legal entities, access trading through these financial intermediaries, such as brokers and banks.

 

ITS Press Service